Shanghai AbelZeta Ltd. clinical trials

A subsidiary of AbelZeta Inc.

The registry lists 18 studies whose lead sponsor is Shanghai AbelZeta Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 16, 2026.

Studies

Recruiting first, then most recently updated. Showing 18 of 18. All AbelZeta Inc. studies →

• A Phase I Trial of A-CAR032 in Participants With mCRPCRecruitingNCT07344311Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• An Phase I Trial of a CAR T-cell Infusion C-CAR031 in Participants With GPC3+ Advanced/Metastatic Squamous Cell Lung CancerRecruitingNCT07444281Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell LymphomaRecruitingNCT05800977Phase 1/2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Study of C-CAR088 in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT05521802Phase 1/2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)Active, not recruitingNCT06590246Phase 1/2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells for the Treatment of Knee OsteoarthritisCompletedNCT04208646Phase 2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular CarcinomaStatus unknownNCT03971747Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL SubjectsCompletedNCT02976857Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage DefectsStatus unknownNCT02855073Phase 2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee OsteoarthritisCompletedNCT02641860Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownNCT03299738Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee OsteoarthritisCompletedNCT02162693Phase 2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Study of Safety and Efficacy of C-CAR011 in B-NHL PatientsStatus unknownNCT03154775Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPCStatus unknownNCT03085966Phase 1/2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALLStatus unknownNCT03018093Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee OsteoarthritisCompletedNCT01809769Phase 1/2

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.Status unknownNCT02704299Early Phase 1

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.

• Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE TherapyCompletedNCT01828762Not applicable

  Sponsor listed in the registry: Shanghai AbelZeta Ltd.